- Home
- CFR vs GKOS Comparison
CFR vs GKOS Comparison
Compare CFR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- GKOS
- Stock Information
- Founded
- CFR 1868
- GKOS 1998
- Country
- CFR United States
- GKOS United States
- Employees
- CFR N/A
- GKOS N/A
- Industry
- CFR Major Banks
- GKOS Medical/Dental Instruments
- Sector
- CFR Finance
- GKOS Health Care
- Exchange
- CFR Nasdaq
- GKOS Nasdaq
- Market Cap
- CFR 6.8B
- GKOS 7.4B
- IPO Year
- CFR N/A
- GKOS 2015
- Fundamental
- Price
- CFR $139.27
- GKOS $138.39
- Analyst Decision
- CFR Hold
- GKOS Strong Buy
- Analyst Count
- CFR 13
- GKOS 12
- Target Price
- CFR $121.92
- GKOS $135.08
- AVG Volume (30 Days)
- CFR 629.8K
- GKOS 600.5K
- Earning Date
- CFR 10-31-2024
- GKOS 11-04-2024
- Dividend Yield
- CFR 2.73%
- GKOS N/A
- EPS Growth
- CFR N/A
- GKOS N/A
- EPS
- CFR 8.07
- GKOS N/A
- Revenue
- CFR $1,964,467,000.00
- GKOS $360,347,000.00
- Revenue This Year
- CFR N/A
- GKOS $22.68
- Revenue Next Year
- CFR $2.73
- GKOS $24.98
- P/E Ratio
- CFR $17.26
- GKOS N/A
- Revenue Growth
- CFR 0.42
- GKOS 18.70
- 52 Week Low
- CFR $94.09
- GKOS $59.22
- 52 Week High
- CFR $144.89
- GKOS $145.84
- Technical
- Relative Strength Index (RSI)
- CFR 63.58
- GKOS 55.15
- Support Level
- CFR $137.72
- GKOS $124.60
- Resistance Level
- CFR $144.89
- GKOS $145.84
- Average True Range (ATR)
- CFR 4.29
- GKOS 5.15
- MACD
- CFR 0.29
- GKOS 0.30
- Stochastic Oscillator
- CFR 74.09
- GKOS 64.92
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost Bankers is a financial holding company, The company offer commercial and consumer banking services, as well as trust and investment management, insurance, brokerage, mutual funds, leasing, treasury management, capital markets advisory and item processing services across Texas in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Permian Basin, Rio Grande Valley, and San Antonio regions.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.